Published in Physician Law Weekly, January 17th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at GlaxoSmithKline.
Report 1: Data presented at the 2006 Annual Scientific Meeting of NAASO, The Obesity Society, found that low-dose orlistat (60 mg) in conjunction with a reduced-calorie diet provided significantly greater reductions in LDL cholesterol and weight loss when compared to treatment with placebo and a reduced-calorie diet.
The data demonstrate that the effect of low-dose orlistat on change in LDL cholesterol persisted even after correcting for weight loss,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.